Who is affected by this change?

This affects Independence Blue Cross Dermatology, Rheumatology providers on Commercial plans.

When does this change take effect?

This change is effective Mar 5, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.01.48b, Tildrakizumab-asmn (Ilumya®)

Independence Blue Cross·Dermatology, Rheumatology·Pharmacy

Effective date

Mar 5, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Commercial insurance policy for Tildrakizumab-asmn (Ilumya®) has been reissued with updates effective March 5, 2025. This is a fresh pharmacy policy change that may affect coverage or billing requirements for this psoriasis medication.

Action Required

Action needed

Before March 5, 2025: Review updated Tildrakizumab-asmn (Ilumya®) policy at the provided URL to identify specific coverage or prior authorization changes. Update billing protocols and staff training accordingly for this specialty psoriasis medication.

Related policy hubs

Independence Blue Cross policies Dermatology Rheumatology